Literature DB >> 23909794

Metabolic syndrome correlates with peri-urethral fibrosis secondary to chronic prostate inflammation: evidence of a link in a cohort of patients undergoing radical prostatectomy.

Francesco Cantiello1, Antonio Cicione, Andrea Salonia, Riccardo Autorino, Giuseppe Ucciero, Luigi Tucci, Alberto Briganti, Rocco Damiano.   

Abstract

OBJECTIVES: To investigate the pathological relationship between metabolic syndrome and peri-urethral fibrosis status secondary to chronic prostate inflammation.
METHODS: Peri-urethral prostate tissue from 80 consecutive patients who underwent retropubic radical prostatectomy for prostate cancer was analyzed. Patients were divided in two groups according to whether or not they had a diagnosis of metabolic syndrome. A 16-peri-urethral core bench biopsy was carried out on each radical prostatectomy specimen to evaluate the extent of peri-urethral inflammatory infiltrate, and collagen and elastin amount. Spearman's correlation analysis was used to test the association between variables. Furthermore, the data were used to define a bivariate logistic regression model in which the presence (>50% collagen amount for each patients) or absence (≤50% collagen amount) of fibrosis was analyzed after adjusting for clinical and pathological variables.
RESULTS: A significant difference was found between the two groups in terms of International Prostatic Symptoms Score (P < 0.05) and urodynamics findings (all P < 0.05). Patients with metabolic syndrome showed a more extended inflammatory infiltrate and higher peri-urethral collagen amount, along with a lower peri-urethral elastin amount (all P < 0.05). A positive correlation was observed between inflammation, International Prostatic Symptoms Score, Bladder Outlet Obstruction Index and collagen amount, whereas inflammation was inversely correlated with elastin amount. On multivariate logistic regression analysis, prostate inflammation and metabolic syndrome were the only independent predictors of peri-urethral fibrosis (OR 1.73, 1.52, respectively).
CONCLUSIONS: The present findings suggest that metabolic syndrome might represent an independent risk factor for prostate inflammation and fibrotic changes secondary to inflammation within the peri-urethral prostatic tissue.
© 2013 The Japanese Urological Association.

Entities:  

Keywords:  lower urinary tract symptoms; metabolic syndrome; peri-urethral fibrosis; prostate inflammation

Mesh:

Year:  2013        PMID: 23909794     DOI: 10.1111/iju.12233

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  5 in total

Review 1.  Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?

Authors:  Granville L Lloyd; Jeffrey M Marks; William A Ricke
Journal:  Curr Urol Rep       Date:  2019-08-03       Impact factor: 3.092

2.  Obesity-initiated metabolic syndrome promotes urinary voiding dysfunction in a mouse model.

Authors:  Qiqi He; Melissa A Babcook; Sanjeev Shukla; Eswar Shankar; Zhiping Wang; Guiming Liu; Bernadette O Erokwu; Chris A Flask; Lan Lu; Firouz Daneshgari; Gregory T MacLennan; Sanjay Gupta
Journal:  Prostate       Date:  2016-04-04       Impact factor: 4.104

3.  Effect of Metabolic Syndrome on Anatomy and Function of the Lower Urinary Tract Assessed on MRI.

Authors:  Alex P Tannenbaum; Matthew D Grimes; Christopher L Brace; Cody J Johnson; Samuel D Koebe; Lucille E Anzia; Lu Mao; William A Ricke; Diego Hernando; Alejandro Roldan-Alzate; Shane A Wells
Journal:  Urology       Date:  2021-09-24       Impact factor: 2.633

4.  Risk Factors associated with Paraurethral Duct Dilatation following Gonococcal Paraurethral Duct Infection in Men.

Authors:  Wenge Fan; Qingsong Zhang; Lin Wang; Xun Ye; Tingwang Jiang
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

5.  A new nomogram of urinary flow rate and volume based on multiple measurements per healthy adult Japanese men using a portable uroflowmeter (P-Flowdiary®).

Authors:  Masatake Shinohara; Kazumasa Torimoto; Chie Matsushita; Daisuke Gotoh; Hisashi Yoshida; Toshihisa Saka; Yoshihiko Hirao; Akihide Hirayama; Kiyohide Fujimoto
Journal:  BMC Urol       Date:  2022-08-25       Impact factor: 2.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.